glutathione synthetase deficiency treatment Glutathione synthetase deficiency | MedLink
Description
Over the last 25 years, more than a dozen drugs representing five drug classes have been developed and approved for the treatment of this devastating disease
BPC-157 Peptide Vial CAS Number 137525-51-0 Other Names BPC157, BPC 157, Bepecin, 8ED8NXK95P, PLD-116, PL-14736, Body protection compound 15 IUPAC Name (4S)-4-[(2-aminoacetyl)amino]-5-[(2S)-2-[(2S)-2-[(2S)-2-[[2-[[(2S)-6-amino-1-[(2S)-2-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[2-[[(2S)-1-[[(1S)-1-carboxy-2-methylpropyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxohexan-2-yl]amino]-2-oxoethyl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-5-oxopentanoic acid Molecular Formula CHNO Molecular Weight 1419.5 Purity 99% Pure (LC-MS) Material Safety Data Sheet (MSDS) View Material Safety Data Sheet Liquid Availability
The γ-glutamyl cycle, comprising six enzymes, harbors four hereditary defects: γ-glutamylcysteine synthetase, glutathione synthetase, γ-glutamyl transpeptidase, and 5-oxoprolinase
- Rapid skin whitening (by reducing the melanin formation)
